ABT Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 84.1% compared to Abbott Laboratories's net margin of 5.86%. Abbott Laboratories's return on equity of 32.63% beat Becton Dickinson &'s return on equity of 6.75%.

Abbott Laboratories has a consensus price target of $140.41, signalling upside risk potential of 8.98%. On the other hand Becton Dickinson & has an analysts' consensus of $273.70 which suggests that it could grow by 33.46%. Given that Becton Dickinson & has higher upside potential than Abbott Laboratories, analysts believe Becton Dickinson & is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.131%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.77%. Becton Dickinson & offers a yield of 1.94% to investors and pays a quarterly dividend of $1.04 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Becton Dickinson & quarterly revenues of $5.2B. Abbott Laboratories's net income of $9.2B is higher than Becton Dickinson &'s net income of $303M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.84x while Becton Dickinson &'s PE ratio is 34.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.37x versus 2.89x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 84.1% compared to Abbott Laboratories's net margin of 14.45%. Abbott Laboratories's return on equity of 32.63% beat Boston Scientific's return on equity of 8.96%.

Abbott Laboratories has a consensus price target of $140.41, signalling upside risk potential of 8.98%. On the other hand Boston Scientific has an analysts' consensus of $117.06 which suggests that it could grow by 14.88%. Given that Boston Scientific has higher upside potential than Abbott Laboratories, analysts believe Boston Scientific is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.77%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Boston Scientific quarterly revenues of $4.7B. Abbott Laboratories's net income of $9.2B is higher than Boston Scientific's net income of $674M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.84x while Boston Scientific's PE ratio is 74.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.37x versus 8.64x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 84.1% compared to Abbott Laboratories's net margin of 30.99%. Abbott Laboratories's return on equity of 32.63% beat Intuitive Surgical's return on equity of 15.82%.

Abbott Laboratories has a consensus price target of $140.41, signalling upside risk potential of 8.98%. On the other hand Intuitive Surgical has an analysts' consensus of $576.56 which suggests that it could grow by 13.47%. Given that Intuitive Surgical has higher upside potential than Abbott Laboratories, analysts believe Intuitive Surgical is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.555, suggesting its more volatile than the S&P 500 by 55.506%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.77%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Abbott Laboratories's net income of $9.2B is higher than Intuitive Surgical's net income of $698.4M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.84x while Intuitive Surgical's PE ratio is 74.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.37x versus 21.17x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 84.1% compared to Abbott Laboratories's net margin of 8.48%. Abbott Laboratories's return on equity of 32.63% beat Stryker's return on equity of 15.22%.

Abbott Laboratories has a consensus price target of $140.41, signalling upside risk potential of 8.98%. On the other hand Stryker has an analysts' consensus of $421.86 which suggests that it could grow by 16.84%. Given that Stryker has higher upside potential than Abbott Laboratories, analysts believe Stryker is more attractive than Abbott Laboratories.

Abbott Laboratories has a beta of 0.803, which suggesting that the stock is 19.666% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Abbott Laboratories has a quarterly dividend of $0.59 per share corresponding to a yield of 1.77%. Stryker offers a yield of 0.91% to investors and pays a quarterly dividend of $0.84 per share. Abbott Laboratories pays 28.62% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Abbott Laboratories quarterly revenues are $11B, which are larger than Stryker quarterly revenues of $6.4B. Abbott Laboratories's net income of $9.2B is higher than Stryker's net income of $546M. Notably, Abbott Laboratories's price-to-earnings ratio is 16.84x while Stryker's PE ratio is 46.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abbott Laboratories is 5.37x versus 6.16x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.